期刊文献+

影响幕上WHOⅢ胶质瘤预后的相关因素分析 被引量:3

The factors effecting on the prognosis of WHO grade Ⅲ glioma
下载PDF
导出
摘要 背景与目的:近年来,国外开展了多宗关于胶质瘤预后因素评估的临床研究,而此类研究在国内尚为数不多。本文旨在以中国人群为样本,分析影响胶质瘤预后相关因素,为临床提供理论依据。方法:收集2009年5月至2010年12月北京天坛医院神经外科四病区外科手术治疗的109例原发性WHOⅢ胶质瘤患者的资料。生存分析中单因素分析采用Kaplan-Meier计算生存率,并采用Log-rank检验进行生存率比较;多因素分析使用Cox比例风险模型,采用逐步回归分析法。结果:单因素分析结果显示病理类型、年龄、1p/19q、IDH1、MGMT与患者预后相关(P<0.05);多因素分析结果显示病理类型、年龄、1p/19q为独立预后因素,而IDH1、MGMT则不能作为独立预后因素。结论:病理类型、年龄、1p/19q可作为评估幕上WHOⅢ胶质瘤患者的独立预后因素;1p/19q共缺失可能是MGMT低表达作为评估患者预后因素的前提条件,而1p/19q共缺失则很可能是通过降低MGMT表达量而增加了患者化疗、放疗敏感性来延长患者的生存期。 BACKGROUND & OBJECTIVE: Recently, several clinical trials which devoted to ascertaining the factors influencing the prognosis of glioma patients had been projected. In China, similar trials were limited. This study which based on Chinese patients with grade III gliomas was designed to assess the roles of several factors in prognosis and provide theoretical reference to clinical treatment. METHODS: A series of 109 grade Ⅲ glioma patients surgically treated and pathologically confirmed in Beijing Tiantan Hospital from May 2009 to December 2010 were respectively reviewed in the study. For the univariate analysis, survival probabilities were estimated based on Kaplan-Meier method and Log-rank test. Multivariate regression analysis using Cox's proportion- hazards model showed the effects of these factors on survival. RESULTS: Univariate analysis revealed that histology type, age, lp/19q, IDH1, and MGMT were all correlated with survival (P〈 0.05). However, only histology type, lp/19q co-deletion and age was confirmed by Cox regression (P〈 0.05). CONCLUSION: Both histology type, age and lp/19q co-deletion are independent predictive factors for survival. MGMT expression is a predictive factor for survival that is dependent on lp/19q co-deletion. Perhaps lp/19q co-deletion is the prerequisite for MGMT lower expression to predict longer survial and lp/19q co-deletion prolong survival by decreasing MGMT expression.
出处 《中国神经肿瘤杂志》 2012年第3期152-157,共6页 Chinese Journal of Neuro-Oncology
基金 北京市自然科学基金(No.7122061)
关键词 幕上 WHOⅢ 胶质瘤 预后 Supratentorial Grade Ⅲglioma Prognosis
  • 相关文献

参考文献3

二级参考文献31

  • 1何杰,郑声琴,乔颖娟,姚青,郭庆明,魏晓莹,黄培林.少突胶质细胞肿瘤染色体1p、19q和10q杂合性缺失与临床预后的关系[J].临床与实验病理学杂志,2006,22(4):444-448. 被引量:10
  • 2张淑坤,卢德宏,朴月善,蔡彦宁,徐庆中.即时荧光定量PCR微卫星分析技术检测少突胶质细胞肿瘤染色体1p/19q杂合性缺失[J].中华病理学杂志,2006,35(12):731-734. 被引量:9
  • 3Cairncross J G,Ueki K,Zlatescu M C,et al.Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.J Nail Cancer Inst,1998,90:1473-1479.
  • 4Kaloshi G,Benouaich-Amiel A,Diakite F,et al.Temozolomide for low-grade gliomas:predictive impact of 1p/19q loss on response and outcome.Neurology,2007,68:1831-1836.
  • 5Jenkins RB,Blair H,Ballman KV,et al.At(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.Cancer Res,2006,66:9852-9861.
  • 6Fontaine D,Vandenbos F,Lebrun C,et al.Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas:critical review of the literature and implications in daily clinical practice.Rev Neurol,2008,164:595-604.
  • 7Reddy KS.Assessment of 1p/19q deletions by fluorescence in situ hybtidization in gliomas.Cancer Genet Cytogenet,2008,184:77-86.
  • 8Kaneshiro D,Kobayashi T,Chao ST,et al.Chromosome 1p and 19q Deletions in Glioblastoma Multiforme.Appl Immunoldstochem Mol Morphol,2009,17:512-516.
  • 9Jeon YK,Park K,Park CK,et al.Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors:a elinicopathological study using fluorescence in situ hybridization.Neuropathology,2007,27:10-20.
  • 10Felsberg J,Erkwoh A,Sabel MC,et al.Oligedendroglial tumors:refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival.Brain Pathol,2004,14:121-130.

共引文献27

同被引文献30

  • 1Cairncross G,Jenkins R.Gliomas with 1p/19q codeletion:a.k.a.oligodendroglioma.Cancer J,2008,14:352-357.
  • 2Yan H,Parsons DW,Jin G,et al.IDH1 and IDH2 mutations in gliomas.N Engl J Med,2009,360:765-773.
  • 3Esteller M,Herman JG.Generating mutations but providing chemosensitivity:the role of O6-methylguanine DNA methyltransferase in human cancer.Oncogene,2004,23:1-8.
  • 4Intergroup Radiation Therapy Oncology Group Trial 9402,Cairncross G,Berkey B,et al.Phase Ⅲ trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma:Intergroup Radiation Therapy Oncology Group Trial 9402.J Clin Oncol,2006,24:2707-2714.
  • 5Sanson M,Marie Y,Paris S,et al.Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.J Clin Oncol,2009,27:4150-4154.
  • 6Kros JM,Gorlia T,Kouwenhoven MC,et al.Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951:assessment of consensus in diagnosis,influence of 1 p/19q loss,and correlations with outcome.J Neuropathol Exp Neurol,2007,66:545-551.
  • 7Smith JS,Perry A,Borell TJ,et al.Alterations of chromosome arms 1 p and 19q as predictors of survival in oligodendrogliomas,astrocytomas,and mixed oligoastrocytomas.J Clin Oncol,2000,18:636-645.
  • 8Winger MJ,Macdonald DR,Cairncross JG.Supratentorial anaplastic gliomas in adults.The prognostic importance of extent of resection and prior low-grade glioma.J Neurosurg,1989,71:487-493.
  • 9Miller CR,Dunham CP,Scheithauer BW,et al.Significance of necrosis in grading of oligodendroglial neoplasms:a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.J Clin Oncol,2006,24:5419-5426.
  • 10Tortosa A,Vi(n)olas N,Villà S,et al.Prognostic implication of clinical,radiologic,and pathologic features in patients with anaplastic gliomas.Cancer,2003,97:1063-1071.

引证文献3

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部